Skip to main content
Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.910
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.940
+0.030 (1.57%)
After-hours: Apr 28, 2026, 7:59 PM EDT

Esperion Therapeutics Revenue

In the year 2025, Esperion Therapeutics had annual revenue of $403.14M with 21.31% growth. Esperion Therapeutics had revenue of $168.45M in the quarter ending December 31, 2025, with 143.73% growth.

Revenue (ttm)
$403.14M
Revenue Growth
+21.31%
P/S Ratio
1.22
Revenue / Employee
$1,371,207
Employees
294
Market Cap
491.64M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025403.14M70.82M21.31%
Dec 31, 2024332.31M215.98M185.66%
Dec 31, 2023116.33M40.86M54.14%
Dec 31, 202275.48M-2.97M-3.79%
Dec 31, 202178.45M-149.10M-65.52%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Emergent BioSolutions 742.90M
Organogenesis Holdings 564.17M
Evolus 297.18M
Ironwood Pharmaceuticals 296.15M
Akebia Therapeutics 236.20M
Canopy Growth 203.04M
Kamada 180.46M
SIGA Technologies 94.57M
Revenue Rankings

ESPR News

More News